Author of

• 10923

  +

  P1.18 - Poster Session 1 - Pathology (ID 175)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10925

    +

    P1.18-002 - Epidermal Growth Factor Receptor Mutations in Primary and Metastatic Adenocarcinomas from a Tertiary Hospital in Sao Paulo, Brazil (ID 98)

    09:30 - 09:30  |  Author(s): S.I. Meireles
    • Abstract

    Background
    Recently, the epidermal growth factor receptor (EGFR) mutation emerges promise as target for molecular therapy in Adenocarcinomas of the lung. However, a number of clinical features are associated with EGFR mutations: women, never-smokers than former or current smokers and Asians than other ethnic groups. Sao Paulo population is made up of a confluence of people of several different origins, from the original Native Americans, with the influx of Portuguese colonizers, Black African slaves, and recent European, Arab and Japanese immigration. Other significant groups include Koreans, Chinese, Paraguayans and Bolivians. The aim of this study was to evaluate the frequency and distribution of EGFR mutations in 100 consecutive patients with surgically excised primary and metastatic Adenocarcinomas.

    Methods
    Direct bidirectional sequencing evaluated EGFR gene mutations on exons 18 to 21 and was correlated with ethnia (East-Asian or European), gender, age, tobacco history, primary (N=75) or metastatic (N=25) and histologic subtypes.

    Results
    Twenty-eight tumors (28%) exhibited EGFR mutation. The most frequent EGFR mutation detected was a deletion in exon 19 (50%), followed by multiple mutations in the exon 20 (28%) and an L858R amino acid substitution in exon 21 (21,4%). EGFR mutation was significantly associated with men (N=59), older patients (>60yrs), smokers, non-East Asian or non-European origins, primary tumor and acinar predominant histologic subtype.

    Conclusion
    Our results indicate that if the current clinical features were strictly followed as the criteria for selecting patients for EGFR testing, a substantial number of patients who might benefit from treatment will be excluded.